These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 33921881)

  • 1. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-A Condition Associated with Heightened Sympathetic Activation.
    Carnagarin R; Tan K; Adams L; Matthews VB; Kiuchi MG; Marisol Lugo Gavidia L; Lambert GW; Lambert EA; Herat LY; Schlaich MP
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic dysfunction-associated fatty liver disease is an early predictor for testosterone deficiency in aging men without metabolic syndrome.
    Liu CC; Huang SP; Lee YC; Lee CH; Huang TY; Geng JH; Chang CW; Lin CY; Juan YS; Wu WJ; Hsieh TJ
    Front Endocrinol (Lausanne); 2023; 14():1252774. PubMed ID: 37854195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of mitochondrial function in metabolic dysfunction-associated fatty liver disease using obese mouse models.
    Zhao QY; Ge LH; Zhang K; Chen HF; Zhan XX; Yang Y; Dang QL; Zheng Y; Zhou HB; Lyu JX; Fang HZ
    Zool Res; 2020 Sep; 41(5):539-551. PubMed ID: 32786176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease.
    Lim S; Kim JW; Targher G
    Trends Endocrinol Metab; 2021 Jul; 32(7):500-514. PubMed ID: 33975804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease.
    Zhang L; El-Shabrawi M; Baur LA; Byrne CD; Targher G; Kehar M; Porta G; Lee WS; Lefere S; Turan S; Alisi A; Weiss R; Faienza MF; Ashraf A; Sundaram SS; Srivastava A; De Bruyne R; Kang Y; Bacopoulou F; Zhou YH; Darma A; Lupsor-Platon M; Hamaguchi M; Misra A; Méndez-Sánchez N; Ng NBH; Marcus C; Staiano AE; Waheed N; Alqahtani SA; Giannini C; Ocama P; Nguyen MH; Arias-Loste MT; Ahmed MR; Sebastiani G; Poovorawan Y; Al Mahtab M; Pericàs JM; Reverbel da Silveira T; Hegyi P; Azaz A; Isa HM; Lertudomphonwanit C; Farrag MI; Nugud AAA; Du HW; Qi KM; Mouane N; Cheng XR; Al Lawati T; Fagundes EDT; Ghazinyan H; Hadjipanayis A; Fan JG; Gimiga N; Kamal NM; Ștefănescu G; Hong L; Diaconescu S; Li M; George J; Zheng MH
    Med; 2024 Jul; 5(7):797-815.e2. PubMed ID: 38677287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Insulin Resistance in MAFLD.
    Sakurai Y; Kubota N; Yamauchi T; Kadowaki T
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease.
    Khanmohammadi S; Kuchay MS
    Pharmacol Res; 2022 Nov; 185():106507. PubMed ID: 36252773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study.
    Chen YL; Li H; Li S; Xu Z; Tian S; Wu J; Liang XY; Li X; Liu ZL; Xiao J; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ
    BMC Gastroenterol; 2021 May; 21(1):212. PubMed ID: 33971822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evil relationship between liver fibrosis and cardiovascular disease in metabolic dysfunction-associated fatty liver disease (MAFLD): Looking for the culprit.
    Fabris L; Campello E; Cadamuro M; Simioni P
    Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):166763. PubMed ID: 37951510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic developments in metabolic dysfunction-associated fatty liver disease.
    Shi Y; Fan J
    Chin Med J (Engl); 2022 May; 135(9):1009-1018. PubMed ID: 35234696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exercise in the Management of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Position Statement from Exercise and Sport Science Australia.
    Keating SE; Sabag A; Hallsworth K; Hickman IJ; Macdonald GA; Stine JG; George J; Johnson NA
    Sports Med; 2023 Dec; 53(12):2347-2371. PubMed ID: 37695493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maternal obesity and metabolic (dysfunction) associated fatty liver disease in pregnancy: a comprehensive narrative review.
    Leca BM; Lagojda L; Kite C; Karteris E; Kassi E; Randeva HS; Kyrou I
    Expert Rev Endocrinol Metab; 2024 Jul; 19(4):335-348. PubMed ID: 38860684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autonomic Regulation of Glucose Homeostasis: a Specific Role for Sympathetic Nervous System Activation.
    Carnagarin R; Matthews VB; Herat LY; Ho JK; Schlaich MP
    Curr Diab Rep; 2018 Sep; 18(11):107. PubMed ID: 30232652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic syndrome: a sympathetic disease?
    Schlaich M; Straznicky N; Lambert E; Lambert G
    Lancet Diabetes Endocrinol; 2015 Feb; 3(2):148-57. PubMed ID: 24731670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Rather a Bystander Than a Driver of Mortality.
    Semmler G; Wernly S; Bachmayer S; Leitner I; Wernly B; Egger M; Schwenoha L; Datz L; Balcar L; Semmler M; Stickel F; Niederseer D; Aigner E; Datz C
    J Clin Endocrinol Metab; 2021 Aug; 106(9):2670-2677. PubMed ID: 33982065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Review of the Increasing Prevalence of Metabolic-Associated Fatty Liver Disease (MAFLD) in Children and Adolescents Worldwide and in Mexico and the Implications for Public Health.
    Ramírez-Mejía MM; Díaz-Orozco LE; Barranco-Fragoso B; Méndez-Sánchez N
    Med Sci Monit; 2021 Aug; 27():e934134. PubMed ID: 34456329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases.
    Gutiérrez-Cuevas J; Santos A; Armendariz-Borunda J
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
    Kang SH; Cho Y; Jeong SW; Kim SU; Lee JW;
    Clin Mol Hepatol; 2021 Apr; 27(2):257-269. PubMed ID: 33751877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight.
    Vasques-Monteiro IML; Souza-Mello V
    World J Gastroenterol; 2021 Apr; 27(16):1738-1750. PubMed ID: 33967554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infections at the nexus of metabolic-associated fatty liver disease.
    Boeckmans J; Rombaut M; Demuyser T; Declerck B; Piérard D; Rogiers V; De Kock J; Waumans L; Magerman K; Cartuyvels R; Rummens JL; Rodrigues RM; Vanhaecke T
    Arch Toxicol; 2021 Jul; 95(7):2235-2253. PubMed ID: 34027561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.